FDA Updates 2024 Language Access Plan

“On Thursday, the FDA released its updated 2024 Language Access Plan, taking another key step toward addressing language barriers that impact health equity and strengthening language access to health information and services for the public, including people with Limited English Proficiency and people with disabilities. The plan also supports FDA efforts to identify interpretation language assistance, translate, and make important documents accessible, as well as digital and web content into multiple languages. The Language Access Program, led by the FDA’s Office of Minority Health and Health Equity, is a part of the FDA’s ongoing work to help individuals make informed decisions about their health.”
FDA’s 2024 plan provides practical guidance and action steps for the Agency and its programs to ensure greater access to its information and services.
Suggested For You
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval

regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals
regulatory intelligence
July 8th, 2024
FDA Works to Reduce the Spread of Misinformation

regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices

regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
regulatory intelligence
June 26th, 2024
New Details on Diversity Action Plans Provided by the US FDA
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

perspectives
July 16th, 2024
Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives
July 9th, 2024
Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives
July 2nd, 2024
Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology